HATTIESBURG, Miss. - When National Science Foundation reviewers approved a $100,000 grant for a startup company in Hattiesburg, reviewers made an interesting comment. "This is very risky but very exciting research," said the NSF reviewers, "and has the potential to be a game-changing cancer therapy." Ablitech combines experts in polymer research and medicinal chemistry to come up with radical products. The latest effort: Ablitech thinks it's found a way to deliver a known cancer killer to the target and protect it from being broken down by the body's enzymes. (Source: Alliance Insight, April 2009)
